title: Disseminated Mycobacterium mantenii infection with multiple purulent cutaneous lesions.
authors.affiliation: Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Honda
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tanizaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Otsuka
authors.forename: Mirei
authors.initials: M
authors.lastname: Shirakashi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Imura
authors.forename: Tsuneyo
authors.initials: T
authors.lastname: Mimori
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Miyachi
authors.forename: Kenji
authors.initials: K
authors.lastname: Kabashima
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D005871:Castleman Disease / Q000150:complications / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D009165:Mycobacterium Infections, Nontuberculous / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D009170:Nontuberculous Mycobacteria; D011239:Prednisolone / Q000009:adverse effects; D017192:Skin Diseases, Bacterial / Q000139:chemically induced / Q000188:drug therapy / Q000382:microbiology*; D016559:Tacrolimus / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D011239:Prednisolone; C502936:tocilizumab; D016559:Tacrolimus